Sinocare

About Sinocare

Sinocare Inc. is a publicly traded, high-tech company based in Changsha, China, that develops, manufactures, and sells rapid diagnostic products for chronic diseases. Founded in 2002 by Shaobo Li, who serves as Chairman and CEO, the company was established with the goal of making blood glucose meters accessible to every person with diabetes in China. The company's business model is centered on the direct sale of medical devices and consumables, such as test strips, to both individual consumers and healthcare professionals.

A significant milestone in the company's history was its listing on the Shenzhen Stock Exchange in 2011, which facilitated further investment in research and development and expanded production capabilities. Sinocare has pursued an aggressive global expansion strategy, notably through key acquisitions. In 2016, the company acquired two US-based firms: Nipro Diagnostic Inc. (now Trividia Health Inc.) and PTS Diagnostics Inc. These acquisitions significantly broadened Sinocare's product portfolio and market presence, particularly in the Americas, incorporating technologies for cholesterol and A1C testing alongside its core glucose monitoring systems. This strategic expansion has positioned Sinocare as the fourth-largest blood glucose meter manufacturer globally and the largest in Asia.

The company's product line leverages biosensor technology and includes a wide array of point-of-care testing devices. The core offerings are blood glucose monitoring (BGM) systems, sold under brand names like Safe-Accu, and multi-parameter systems that can also test for uric acid and blood ketones. Responding to market evolution, Sinocare has developed continuous glucose monitoring (CGM) systems, such as the iCan CGM, and provides digital health management solutions that integrate with their devices. Beyond diabetes care, the portfolio extends to blood pressure monitors, lipid analyzers, and other health monitoring products for home and clinical use. While facing strong competition from global players like Abbott and Roche, Sinocare differentiates itself by focusing on affordability and accessibility, which has allowed it to secure a substantial market share, especially in China and other emerging markets.